Limerston Capital has acquired Concept Life Sciences, a leading integrated drug discovery, development and manufacturing organisation, in a carve-out from Spectris plc, through its new fund Limerston Capital Partners II, LP.
The acquisition is Limerston’s fourth platform deal in the life sciences space. The firm targets UK businesses with EBITDA of between £5 million and £15 million.
Concept Life Sciences is an established contract research organisation (CRO), primarily serving the global research and development market, with clients in the pharmaceutical and biotechnology space ranging from blue chip to virtual biotech.
Its team of around 300 accomplished scientists and over 100 PhDs operate from laboratory facilities, strategically located in major science hubs across the UK.
Newly appointed CEO, Dr Ben Cliff, will be responsible for a new growth strategy which will see Concept Life Sciences take advantage of its increased commercial and technical flexibility to build and expand its services to a new and existing client base.
